Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

THERAPY

Combining options in metastatic prostate cancer

Nature Reviews Urology volume 16, pages 569–570 (2019)Cite this article

Subjects

Intensifying systemic therapy improves outcomes in metastatic prostate cancer. As apalutamide and enzalutamide join abiraterone and docetaxel as treatment options for patients, the choice of therapy for individual patients becomes more complex. We anticipate precision targeted and immune therapies will build on the advances of recently completed large-scale trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Chi, K. N. et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 381, 13–24 (2019).

    Article  CAS  Google Scholar 

  2. Davis, I. D. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381, 121–131 (2019).

    Article  Google Scholar 

  3. Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate vancer. N. Engl. J. Med. 373, 737–746 (2015).

    Article  CAS  Google Scholar 

  4. Crawford, E. D. et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 321, 419–424 (1989).

    Article  CAS  Google Scholar 

  5. Prostate Cancer Trialists’ Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355, 1491–1498 (2000).

    Article  Google Scholar 

  6. Kyriakopoulos, C. E. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J. Clin. Oncol. 36, 1080–1087 (2018).

    Article  CAS  Google Scholar 

  7. Gravis, G. et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. Eur. Urol. 73, 847–855 (2018).

    Article  Google Scholar 

  8. Fizazi, K. et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377, 352–360 (2017).

    Article  CAS  Google Scholar 

  9. James, N. D. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. 377, 338–351 (2017).

    Article  CAS  Google Scholar 

  10. Sydes, M. R. et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann. Oncol. 29, 1235–1248 (2018).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Oregon Health & Science University, Portland, OR, USA

    Ryan P. Kopp

  2. Urology Section, Portland VA Medical Center, Portland, OR, USA

    Ryan P. Kopp

  3. Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA

    Ryan P. Kopp & Tomasz M. Beer

Authors
  1. Ryan P. Kopp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomasz M. Beer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomasz M. Beer.

Ethics declarations

Competing interests

T.M.B. has received research funding from Alliance Foundation Trials, Boehringer Ingelheim, Corcept Therapeutics, Endocyte Inc., Janssen Research & Development, Medivation, Inc./Astellas, OncoGenex, Sotio and Theraclone Sciences/OncoResponse, consulting fees from AbbVie, Astellas Pharma, AstraZeneca, Bayer, Boehringer Ingelheim, Clovis Oncology, GlaxoSmithKline, Janssen Biotech, Janssen Japan, Merck and Pfizer and owns stock in Salarius Pharmaceuticals. R.P.K. has received research funding from Merck and Roche.

Additional information

Related links

NCT01957436: https://clinicaltrials.gov/ct2/show/NCT01957436

NCT02799602: https://clinicaltrials.gov/ct2/show/NCT02799602

NCT03678025: https://clinicaltrials.gov/ct2/show/NCT03678025

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kopp, R.P., Beer, T.M. Combining options in metastatic prostate cancer. Nat Rev Urol 16, 569–570 (2019). https://doi.org/10.1038/s41585-019-0217-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-019-0217-z

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing